Neurogene
NGNE
82 hedge funds and large institutions have $230M invested in Neurogene in 2025 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 27 increasing their positions, 29 reducing their positions, and 12 closing their positions.
175% more call options, than puts
Call options by funds: $1.59M | Put options by funds: $580K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
19% more capital invested
Capital invested by funds: $193M → $230M (+$37.3M)
7% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 29
2.34% less ownership
Funds ownership: 110.24% → 107.9% (-2.3%)
4% less funds holding
Funds holding: 85 → 82 (-3)
25% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$6.94M |
| 2 |
Morgan Stanley
New York
|
+$4.07M |
| 3 |
Millennium Management
New York
|
+$2.35M |
| 4 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$2.26M |
| 5 |
Jennison Associates
New York
|
+$933K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
-$7.8M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$7.76M |
| 3 |
BlackRock
New York
|
-$6.61M |
| 4 |
DM
Deerfield Management
New York
|
-$5.23M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$1.37M |
NGNE Hedge Fund Activity: Q2 2025 in Review
82 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Neurogene (NGNE) for Q2 2025, worth a combined $230M — up 19% from $193M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of NGNE and 9 opened new positions — a net loss of 3 holders — while 29 trimmed existing stakes and 27 added.
The largest buyer was Toronto Dominion Bank, adding an estimated $6.94M. The largest seller was Commodore Capital, cutting an estimated $7.8M.
- 82 institutional investors held Neurogene (NGNE) as of Q2 2025, down from 85 in Q1 2025.
- Funds reported $230M of Neurogene stock for Q2 2025, up 19% quarter-over-quarter.
- 9 funds opened new Neurogene positions in Q2 2025 and 12 closed out, a net change of -3 holders.
- The largest Neurogene buyer in Q2 2025 was Toronto Dominion Bank, an estimated $6.94M added.
- The largest Neurogene seller in Q2 2025 was Commodore Capital, an estimated $7.8M sold.
Based on aggregated 13F filings for Q2 2025.